Bausch + Lomb Corporation (BLCO) |
|
17.41 0.36 (2.11%)
|
03-31 16:00 |
|
Open: |
17.11 |
Pre. Close: |
17.05 |
|
High:
|
17.5 |
Low:
|
17.1 |
|
Volume:
|
296,448 |
Market Cap:
|
6,094(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:17:10 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 21.54  One year: 25.16 |
| Support: |
Support1: 16.44 Support2: 15.21 |
| Resistance: |
Resistance1: 18.45 Resistance2: 21.54 |
| Pivot: |
16.29  |
| Moving Average: |
MA(5): 16.89 MA(20): 16.38
MA(100): 16.2 MA(250): 0 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 93.2 %D(3): 84.7 |
| RSI: |
RSI(14): 59.2 |
| 52-week: |
High: 19.18 Low: 12.19 |
| Average Vol(K): |
3-Month: 369 (K) 10-Days: 290 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLCO ] has closed Bollinger Bands are 0.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.16 - 17.21 |
17.21 - 17.26 |
|
Low:
|
16.53 - 16.59 |
16.59 - 16.66 |
|
Close:
|
16.94 - 17.03 |
17.03 - 17.14 |
|
Company Description |
|
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada. |
Headline News |
Mon, 27 Mar 2023
Bausch + Lomb Co. (NYSE:BLCO) Receives Consensus ... - MarketBeat
Wed, 22 Mar 2023
Bausch + Lomb and Novaliq Announce Publication of Second ... - Business Wire
Tue, 14 Mar 2023
Bausch + Lomb Co. (NYSE:BLCO) Short Interest Up 15.9% in ... - MarketBeat
Sun, 12 Mar 2023
Nomura Holdings Inc. Takes Position in Bausch + Lomb Co. (NYSE ... - MarketBeat
Thu, 09 Mar 2023
Tracking Carl Icahn's Portfolio – Q4 2022 Update (NASDAQ:IEP) - Seeking Alpha
Mon, 27 Feb 2023
Bausch + Lomb: Brent Saunders Return Bodes Well For ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Medical Instruments & Supplies |
| Shares Out. |
350 (M) |
| Shares Float |
40 (M) |
|
% Held by Insiders
|
88.7 (%) |
|
% Held by Institutions
|
13 (%) |
|
Shares Short
|
7,430 (K) |
|
Shares Short P.Month
|
5,990 (K) |
Stock Financials |
|
EPS
|
0.01 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
20.09 |
|
Profit Margin (%)
|
0.1 |
|
Operating Margin (%)
|
5.8 |
|
Return on Assets (ttm)
|
1.2 |
|
Return on Equity (ttm)
|
0.1 |
|
Qtrly Rev. Growth
|
-0.5 |
|
Gross Profit (p.s.)
|
6.42 |
|
Sales Per Share
|
10.77 |
|
EBITDA (p.s.)
|
1.71 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
345 (M) |
|
Levered Free Cash Flow
|
184 (M) |
Stock Valuations |
|
PE Ratio
|
871.5 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.86 |
|
Price to Sales
|
1.61 |
|
Price to Cash Flow
|
17.68 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
